EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Optimizing Communication on HPV Vaccination to Parents of 11- to 14-Year-Old Adolescents in France: A Discrete Choice Experiment

Sandra Chyderiotis, Jonathan Sicsic, Amandine Gagneux-Brunon, Jocelyn Raude, Anne-Sophie Barret, Sébastien Bruel, Aurélie Gauchet, Anne-Sophie Le Duc Banaszuk, Morgane Michel, Bruno Giraudeau, Nathalie Thilly, Judith E Mueller iD und 1 weitere

The Patient - Patient-Centered Outcomes Research · 2024

DOI: 10.1007/s40271-024-00687-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Patient - Patient-Centered Outcomes Research, 2024. Verfasst von Sandra Chyderiotis und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institut Pasteur, Université Paris Cité, Emerging Disease Epidemiology Unit, 75015, Paris, France. Hauptthemen laut MEDLINE: Papillomavirus Vaccines, Parents, Papillomavirus Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ITMO Cancer AVIESAN.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: With the aim to optimize communication during HPV vaccination campaigns in France, we elicited parental preferences around HPV vaccination. METHODS: We conducted a single-profile discrete choice experiment (DCE) among parents of 11- to 14-year-old middle-school pupils, who completed an anonymous, self-administered, internet-based questionnaire during 2020-2021. The DCE comprised five attributes (vaccine-preventable disease, justification of optimal age, information on safety, indirect protection and coverage) of vaccination against an unnamed disease that were presented to respondents in ten choice tasks, or scenarios. We use fixed effect logit models to estimate attribute weights on theoretical vaccine acceptance, and random effect linear regression to estimate attribute coefficients on vaccine eagerness (decision and decision certainty). We estimated marginal effects of attributes on expected vaccine acceptance. RESULTS: Vaccination scenarios were accepted by 55.6-89.2% of the 1291 participants. The largest marginal effects on expected vaccine acceptance in the full sample arose from prevention of cancer versus genital warts (+ 11.3 percentage points); from a "severe side effect suspicion that was not scientifically confirmed" versus a statement about "more benefits than risks" (+ 8.9 percentage points), and information on 80% vaccine coverage in neighbouring countries versus on "insufficient coverage" (+ 4.2 percentage points). Explaining the early age of vaccination by sexual debut had a strong negative impact among French monolingual parents with lower education level (vs age-independent, OR 0.48, 95% CI 0.27-0.86), but not other socio-economic groups. After removing low-quality responses (unvaried certainty and short questionnaire completion), among serial non-demanders with children not vaccinated against HPV, only disease elimination impacted vaccine eagerness positively (coefficient 0.54, 0.06-1.02). DISCUSSION: Using DCEs to elicit parents' preferences around communication messages, notably on cancer prevention, vaccine coverage and information about vaccine safety, could help to optimize HPV vaccination promotion efforts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus VaccinesParentsPapillomavirus InfectionsHumansAdolescentFranceFemaleMaleChildSurveys and QuestionnairesAdultVaccinationChoice BehaviorCommunicationHealth Knowledge, Attitudes, PracticeMiddle AgedPatient Acceptance of Health Care

Substanzen

Papillomavirus Vaccines

Autor:innen und Institutionen

  • Institut Pasteur, Université Paris Cité, Emerging Disease Epidemiology Unit, 75015, Paris, France.
  • Université Paris Cité, LIRAES, 75006, Paris, France.
  • CHU de Saint-Etienne-Service d'Infectiologie, Saint-Etienne, France.
  • Centre International de Recherche en Infectiologie, Team GIMAP, Université de Lyon, Université Jean Monnet, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR530, Lyon, France.
  • CIC-Inserm, 1408, CHU de Saint-Etienne, Saint-Etienne, France.
  • Univ. Rennes, EHESP, CNRS, Inserm, Arènes-UMR 6051, RSMS (Recherche sur les Services et Management en Santé)-U1309, 35000, Rennes, France.

ORCID-Profile: Judith E Mueller

Förderung

  • ITMO Cancer AVIESAN

Zitieren

APA

Chyderiotis, S., Sicsic, J., Gagneux-Brunon, A., Raude, J., Barret, A. S., Bruel, S., Gauchet, A., Le Duc Banaszuk, A. S., Michel, M., Giraudeau, B., Thilly, N., Mueller, J. E., & PrevHPV Consortium (2024). Optimizing Communication on HPV Vaccination to Parents of 11- to 14-Year-Old Adolescents in France: A Discrete Choice Experiment. The Patient - Patient-Centered Outcomes Research. https://doi.org/10.1007/s40271-024-00687-6

Vancouver

Chyderiotis S, Sicsic J, Gagneux-Brunon A, Raude J, Barret AS, Bruel S, et al. Optimizing Communication on HPV Vaccination to Parents of 11- to 14-Year-Old Adolescents in France: A Discrete Choice Experiment. The Patient - Patient-Centered Outcomes Research. 2024. doi:10.1007/s40271-024-00687-6

BibTeX
@article{Chyderiotis2024,
  author = {Chyderiotis, Sandra and Sicsic, Jonathan and Gagneux-Brunon, Amandine and Raude, Jocelyn and Barret, Anne-Sophie and Bruel, Sébastien and Gauchet, Aurélie and Le Duc Banaszuk, Anne-Sophie and Michel, Morgane and Giraudeau, Bruno and Thilly, Nathalie and Mueller, Judith E and PrevHPV Consortium, PrevHPV Consortium},
  title = {Optimizing Communication on HPV Vaccination to Parents of 11- to 14-Year-Old Adolescents in France: A Discrete Choice Experiment},
  journal = {The Patient - Patient-Centered Outcomes Research},
  year = {2024},
  doi = {10.1007/s40271-024-00687-6}
}
Kostenlos starten →